Last update 23 Jan 2025

c-Met x DNA

Basic Info

Related Targets
c-MetDNA

Related

1
Drugs associated with c-Met x DNA
BYON-3521
Target
DNA x c-Met
Mechanism
DNA inhibitors [+2]
Active Org.
Byondis BVByondis BV
Originator Org.
Syntarga BVSyntarga BV
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with c-Met x DNA
NL-OMON56017
/ RecruitingNot ApplicableIIT
A first-in-human dose-escalation and expansion study with the antibody-drug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-MET expressing locally advanced or metastatic solid tumours. - Phase1 study in patients with advanced or metastatic solid tumours
NCT05323045
/ Active, not recruitingPhase 1
A First-in-human Dose-escalation and Expansion Trial With the Antibody-drug Conjugate BYON3521 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With c-MET Expressing Locally Advanced or Metastatic Solid Tumours
100 Clinical Results associated with c-Met x DNA
Login to view more data
100 Translational Medicine associated with c-Met x DNA
Login to view more data
0 Patents (Medical) associated with c-Met x DNA
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free